Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)

Next Previous
Search
Trial Profile

Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Feb 2016 Planned End Date changed from 1 April 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
  • 12 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
  • 12 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Sep 2011 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top